Beigene

This study tests whether adding new drugs to the cancer treatment tislelizumab (with or without chemotherapy) can shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer who haven't had treatment before. About 400 participants will join, split into …

This study tests whether a new targeted drug (zanubrutinib) plus rituximab works better than standard chemotherapy (bendamustine) plus rituximab for people with mantle cell lymphoma who haven't had treatment and can't have a stem cell transplant. About 510 adults aged 60 or older…

This study tests whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy can help control advanced colorectal cancer that has not spread further. About 113 adults with a specific type of colorectal cancer (MSS/pMMR) that cannot be removed …

This study tests whether adding the experimental drug LBL-007 to standard immunotherapy (tislelizumab) and chemotherapy helps shrink tumors or delay cancer growth in people with advanced esophageal cancer that cannot be removed by surgery. About 118 adults with this type of cance…

This early-phase study tests a new drug called BGB-11417 in 64 adults with certain types of blood cancers (B-cell malignancies) that have come back or not responded to prior treatments. The main goals are to find the safest dose and check for side effects. This is not a cure; the…

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer who have responded well to chemotherapy. The goal is to see if taking this pill daily can delay the cancer from coming back. The trial involves 224 participants …

This study tests whether combining two immunotherapy drugs (BGB-A445 and tislelizumab) can shrink tumors in people with advanced bladder, kidney, or skin cancer that has spread. About 113 participants who have already tried at least one prior treatment will receive the drug combo…

This phase 3 study tests whether the targeted drug zanubrutinib works better than the standard combination of bendamustine and rituximab for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 590 participants who cannot take stronger chemo wil…

This early-stage study tests an experimental drug called BGB-15025, either alone or with an immunotherapy drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if t…

This study tests a new drug called BGB-11417 (sonrotoclax) for people with mantle cell lymphoma that has returned or stopped responding to other treatments. The drug works by blocking a protein that helps cancer cells survive. The trial has two parts: first, finding the safest do…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants receive either tislelizumab plus chemo or a placebo plus chemo, foll…

This study tests whether combining the drug tislelizumab with other experimental drugs can shrink tumors or slow cancer growth in people with advanced head and neck cancer that has come back or spread. About 160 adults whose cancer cannot be cured with local treatments will recei…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab or a placebo, along wit…

This study looks at the long-term safety of the drug zanubrutinib in people with B-cell cancers (a type of blood cancer) who were already in a related trial. About 955 participants will continue or start zanubrutinib and be monitored for side effects and how well the drug control…

This study tests an experimental drug called BGB-45035 in adults with moderate to severe rheumatoid arthritis who haven't gotten enough relief from standard treatments. About 49 participants will receive either the drug or a placebo to see if it reduces joint pain and swelling. T…

This study tests an experimental drug called BGB-11417 in 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. The goal is to see if the drug can shrink or eliminate cancer cells. Particip…

This study tests different dosing schedules for the drug sonrotoclax in 56 adults with chronic lymphocytic leukemia (CLL). The goal is to find a safer way to start treatment and reduce the risk of tumor lysis syndrome, a serious side effect. Participants receive sonrotoclax in gr…

This early-stage study tests a new drug, BGB-16673, in adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger). The main goal is to check safety and how the drug moves through the body. About 34 participants will receive either the drug or a placebo, …